Developer docs
API playgroundTry for free, no card

Search company profiles

Aptamer Sciences

Full company profile

uuid000d26x

Namestring
Aptamer Sciences
Legal namestring
Aptamer Sciences, Inc.
Websiteurl
aptsci.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Aptamer Sciences, Inc. (KOSDAQ: 291650), founded in 2011 as a POSTECH spin-off and headquartered in Pangyo, South Korea, develops aptamer-based platforms for oncology therapeutics and in vitro diagnostics. The company's proprietary technology uses modified-nucleic-acid SELEX to generate single-stranded DNA/RNA aptamers that selectively bind target proteins, achieving 80%+ selection success rates and up to 100x binding affinity improvement over first-generation aptamers. Core product franchises include the AptoDetect-Lung diagnostic kit (the world's first aptamer-based IVD, approved in Korea in 2017 and CE-marked in 2018), the ApDC (Aptamer-Drug Conjugate) therapeutic platform with proprietary branched linker-payload technology enabling 1-3 drug molecules per aptamer, the AptoMIA multi-biomarker diagnostic platform (7-biomarker Luminex-based panel with proprietary risk-scoring algorithm), and a BBB shuttle platform using TfR aptamers for CNS drug delivery.

The therapeutic pipeline is anchored by AST-201 (GPC3-targeted ApDC for hepatocellular carcinoma, Phase 1 with unusually rapid three-month Cohort 3 progression and MSD/Merck Phase 2 combination trial with Keytruda signed April 2026), AST-203 (TROP2-targeted MMAE-conjugated ApDC, 8x higher tumor penetration than Trodelvy in preclinical models), AST-202 (linker-based ApDC), an ApRC radiopharmaceutical platform, and an insulin receptor aptamer for diabetes (USPTO-granted). Revenue is generated through four streams: diagnostic kit sales (AptoDetect-Lung at ~KRW 200,000/test, currently non-insurance with reimbursement pending), technology out-licensing and royalty arrangements (Appidi Healthcare exclusive supply-plus-royalty for India/South Asia), CRO bioanalysis services (ISS-acquired GLP/GCLP LC-MS/MS capabilities), and prospective pharma licensing of pipeline assets.

Short descriptiontext

Aptamer Sciences is a South Korean KOSDAQ-listed biotech developing aptamer-based diagnostics (AptoDetect-Lung IVD) and oncology therapeutics (ApDC platform) including AST-201 for liver cancer and AST-203 for solid tumors, serving global pharma partners, Korean hospitals, and South Asia via Appidi Healthcare.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGyeongju, South Korea
HQ citystring
Gyeongju
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aptamer therapeutics, cancer diagnostics, drug conjugates, bioanalysis services, targeted drug delivery
Industry5 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code5 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code4 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
Product category
Aptamer-based biotechnology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Kit Sales (AptoDetect-Lung)
TypeHardware Sales
Description

Sales of lung cancer early detection diagnostic kit (AptoDetect-Lung) to hospitals and medical institutions in Korea and international markets through partnership agreements.

aptsci.com
2Technology Licensing/Out-licensing
TypeLicensing Royalties
Description

License-out deals for ApDC platform pipeline assets (AST-201, AST-202, AST-203, BBB shuttle) to global pharmaceutical companies. Target upfront payments of 480 billion KRW for AST-201 and 200 billion KRW for AST-202.

aptsci.com
3CRO Services
TypeProfessional Services
Description

Revenue from biotech analysis services including GLP/GCLP compliant LC-MS/MS analysis, ADA evaluation, and high-difficulty biomolecular analysis. Acquired ISS (International Scientific Standards) in 2024 for CRO expansion.

aptsci.com
4Aptamer Material Supply & Royalties
TypeLicensing Royalties
Description

Supply of proprietary aptamer materials to partners for diagnostic kit manufacturing, plus ongoing royalty payments based on sales revenue generated by partners (e.g., Appidi Healthcare partnership for India/South Asia).

aptsci.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details2 tiers
1AptoDetect-Lung lung cancer diagnostic test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Non-insurance price approximately 200,000 KRW per test (about 100,000 KRW with insurance). Competitor products from overseas (e.g., Oncimmune EarlyCDT-Lung) priced at approximately 600,000 KRW, making Aptamer Sciences significantly more cost-competitive.

aptsci.com
2AptoDetect-Lung uses only 5µL of blood per test
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Requires only 5µL of blood vs competitors requiring 20-3,500µL. Each kit can process up to 88 tests vs competitors at 10-32 tests per kit.

aptsci.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1ApDC
Description

Aptamer-Drug Conjugate platform technology for targeted drug delivery in cancer treatment

aptsci.com
+5 more records
Core offering1 text field

Aptamer Sciences develops and commercializes aptamer-based technology platforms spanning two business segments. The diagnostics segment is anchored by AptoDetect-Lung, an in vitro diagnostic kit measuring seven protein biomarkers via Luminex detection for early-stage non-small cell lung cancer detection. The therapeutics segment is built on the ApDC (Aptamer-Drug Conjugate) platform, using modified-nucleic-acid aptamers with proprietary branched linker technology to deliver cytotoxic drugs, radionuclides, and siRNA payloads, with pipeline candidates AST-201 (GPC3-targeted, Phase 1 for liver cancer) and AST-203 (TROP2-targeted, preclinical for pancreatic cancer). The company also operates a GLP/GCLP-compliant CRO bioanalysis business and offers FDA regulatory consulting services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • AptoDetect-Lung: Sensitivity 75%, Specificity 92% for NSCLC (Stage I-IV)
+4 more records
Product overview1 text field

Aptamer Sciences develops and commercializes aptamer-based products across two business segments: (1) Diagnostics — anchored by the AptoDetect™-Lung lung cancer early detection kit, which uses the proprietary AptoMIA platform to measure 7 blood protein biomarkers via Luminex technology and a proprietary algorithm for lung cancer risk scoring; (2) New Drug Development — anchored by the ApDC® (Aptamer-Drug Conjugate) platform, which uses modified-nucleic-acid aptamers with proprietary branched linker technology to deliver cytotoxic drugs, radionuclides, siRNA, and immunomodulators. Key pipeline candidates include AST-201 (GPC3-targeted ApDC for liver cancer, Phase 1), AST-203 (Trop2-targeted MMAE-conjugated ApDC for solid tumors), BBB Shuttle aptamer platform for brain drug delivery, and an insulin receptor allosteric agonist aptamer (AST-101) for diabetes. The company also operates a GLP/GCLP-compliant CRO providing LC-MS/MS bioanalysis and FDA consulting services.

Product and service3 records
1AptoDetect-Lung
CategoryCancer Diagnostics
Description

In vitro diagnostic medical device for early detection of non-small cell lung cancer (NSCLC), measuring 7 protein biomarkers (EGFR1, MMP7, CA6, KIT, CRP, C9, SERPINA3) from 5µL of blood using Luminex-based detection and a proprietary algorithm to generate lung cancer risk scores. Sold to hospitals and medical institutions in Korea and select international markets.

2CRO Analysis Services
CategoryContract Research Services
Description

GLP/GCLP-compliant bioanalysis services including LC-MS/MS drug analysis, anti-drug antibody (ADA) evaluation, and high-resolution mass spectrometry for metabolite identification. Specialized in high-difficulty biomolecule analysis (peptides, oligonucleotides, ApDC, antibodies) for biotech and pharmaceutical clients requiring IND/NDA support.

3FDA Analysis Consulting
CategoryRegulatory Consulting Services
Description

Regulatory consulting service covering FDA-compliant study design, data generation, documentation, and report quality standards for biotech and pharmaceutical clients preparing for US regulatory submissions.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Clinical Trial Collaboration and Supply Agreement (CTCSA) for AST-201 + Keytruda (pembrolizumab) combination therapy evaluation. Aptamer Sciences will conduct Phase 2 trial; MSD supplies Keytruda and provides scientific collaboration. Represents transition from monotherapy to combination immunotherapy development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Joint development of aptamer-based bispecific siRNA therapeutic platform. Combines Aptamer Sciences' tissue-specific aptamers with Curigin's dual-targeting siRNA technology for precision gene silencing. Expandable to cancer, inflammatory diseases, fibrosis, and neurodegenerative disorders.

3Appidi Healthcare (압피디 헬스케어)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-20
Description

Commercialization partnership for AptoDetect-Lung lung cancer diagnostic kit in India and South Asia (Bangladesh, Nepal, Sri Lanka). Appidi handles local manufacturing, clinical trials, regulatory approval, and distribution. Aptamer Sciences supplies aptamer materials and earns royalties on sales.

aptsci.com
4Selki (셀키)
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-04-24
Description

MOU for biotech analysis innovation combining Aptamer Sciences' FDA regulatory expertise and GLP/GCLP analysis services with Selki's AI-based multiomics analysis capabilities and Agentic LLM platform. Aims to elevate ADC and biopharmaceutical analysis quality to FDA standards.

aptsci.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-06-27
Description

Radiopharmaceutical research collaboration for aptamer-based radionuclide delivery platform. Published in Pharmaceutics journal (top 10%); demonstrated successful 68Ga labeling and PET imaging with EGFRvIII-targeted aptamer in glioblastoma models.

6International Scientific Standards (ISS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-12
Description

Acquired ISS (now Aptamer Sciences CRO Center) to expand into GLP/GCLP bioanalysis services for biopharmaceuticals. ISS has 160+ validated analytical methods and completed 110+ clinical analysis projects over 4 years with major Korean pharma companies.

aptsci.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2022-03-22
Description

Joint research on BBB shuttle aptamer-based Parkinson's disease treatment combining Aptamer Sciences' TfR aptamer with NeuraMedi's anti-TLR2 antibody (Tomaralimab) for enhanced brain delivery of therapeutic antibodies.

8Asymchem (카이라이잉/凯莱英)
Strategic tierSupportingTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-02-04
Description

CDMO partnership for AST-201 clinical trial material manufacturing and supply. Chinese CDMO for GMP production of aptamer-drug conjugate clinical supplies.

aptsci.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2021-06-02
Description

Joint research on ApDC-based targeted anticancer drug development for glioblastoma and pancreatic cancer. Combines Aptamer Sciences' targeting aptamers with Pinobio's linker-drug conjugation and efficacy evaluation capabilities.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Japanese pharma behind Enhertu (HER2 ADC) and Datroway (TROP2 ADC) - the dominant ADC player. Directly relevant as ApDC competes with ADC technology and the same TROP2 target (AST-203 vs Trodelvy/Datroway).

TypeBroad incumbent
Description

Owns Trodelvy (TROP2 ADC via Immunomedics acquisition), the direct competitor for AST-203. Comparable as a large pharma with both ADC platform and oncology diagnostics (via Foundation Medicine).

TypeBroad incumbent
Description

Co-developer of Enhertu and Datroway with Daiichi Sankyo. Also active in radioconjugates and lung cancer diagnostics. Relevant incumbent for ApDC out-licensing competitive landscape.

TypeDirect peer
Description

European clinical-stage biotech developing Spiegelmer aptamer-based therapeutics for cancer. Closest direct peer as a pure-play aptamer therapeutic company, though focused on different targets.

TypeDirect peer
Description

UK-based company behind EarlyCDT-Lung blood-based lung cancer diagnostic, directly comparable to AptoDetect-Lung. The cost comparison (AptoDetect at ~$150 vs EarlyCDT at ~$450) frames the competitive positioning.

TypeBroad incumbent
Description

US liquid biopsy leader (Guardant360, Shield) for oncology diagnostics using blood-based biomarker analysis. Comparable in the multi-biomarker blood test approach used in AptoMIA technology, though at much greater scale.

TypeDirect peer
Description

Radiopharmaceutical company developing diagnostic and therapeutic radioligand therapies (Illuccix, PSMA imaging). Directly comparable to Aptamer Sciences' ApRC platform for aptamer-based radioconjugates in cancer.

TypeDirect peer
Description

US biotech specializing in BBB-penetrant therapeutics for neurodegeneration using transferrin receptor (TfR) engineering. Highly comparable to Aptamer Sciences' BBB Shuttle TfR aptamer platform for CNS drug delivery.

TypeRegional player
Description

Korean ADC developer (KOSDAQ-listed) with similar therapeutic focus on antibody-drug conjugates. Comparable as a domestic Korean peer pursuing next-generation targeted cancer therapies, though using antibodies rather than aptamers.

TypeEmerging player
Description

Korean siRNA therapeutics company and Aptamer Sciences' joint development partner for aptamer-siRNA conjugates. Partial overlap given the collaboration; represents emerging competition in the targeted RNA therapeutics space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aptamer Sciences

Aptamer-based biotechnologyaptsci.com

Aptamer Sciences is a South Korean KOSDAQ-listed biotech developing aptamer-based diagnostics (AptoDetect-Lung IVD) and oncology therapeutics (ApDC platform) including AST-201 for liver cancer and AST-203 for solid tumors, serving global pharma partners, Korean hospitals, and South Asia via Appidi Healthcare.

What Aptamer Sciences does

Aptamer Sciences, Inc. (KOSDAQ: 291650), founded in 2011 as a POSTECH spin-off and headquartered in Pangyo, South Korea, develops aptamer-based platforms for oncology therapeutics and in vitro diagnostics. The company's proprietary technology uses modified-nucleic-acid SELEX to generate single-stranded DNA/RNA aptamers that selectively bind target proteins, achieving 80%+ selection success rates and up to 100x binding affinity improvement over first-generation aptamers. Core product franchises include the AptoDetect-Lung diagnostic kit (the world's first aptamer-based IVD, approved in Korea in 2017 and CE-marked in 2018), the ApDC (Aptamer-Drug Conjugate) therapeutic platform with proprietary branched linker-payload technology enabling 1-3 drug molecules per aptamer, the AptoMIA multi-biomarker diagnostic platform (7-biomarker Luminex-based panel with proprietary risk-scoring algorithm), and a BBB shuttle platform using TfR aptamers for CNS drug delivery.

The therapeutic pipeline is anchored by AST-201 (GPC3-targeted ApDC for hepatocellular carcinoma, Phase 1 with unusually rapid three-month Cohort 3 progression and MSD/Merck Phase 2 combination trial with Keytruda signed April 2026), AST-203 (TROP2-targeted MMAE-conjugated ApDC, 8x higher tumor penetration than Trodelvy in preclinical models), AST-202 (linker-based ApDC), an ApRC radiopharmaceutical platform, and an insulin receptor aptamer for diabetes (USPTO-granted). Revenue is generated through four streams: diagnostic kit sales (AptoDetect-Lung at ~KRW 200,000/test, currently non-insurance with reimbursement pending), technology out-licensing and royalty arrangements (Appidi Healthcare exclusive supply-plus-royalty for India/South Asia), CRO bioanalysis services (ISS-acquired GLP/GCLP LC-MS/MS capabilities), and prospective pharma licensing of pipeline assets.

Aptamer Sciences firmographics

Firmographics
Name
Aptamer Sciences
Legal name
Aptamer Sciences, Inc.
Website
https://aptsci.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Aptamer Sciences is a South Korean KOSDAQ-listed biotech developing aptamer-based diagnostics (AptoDetect-Lung IVD) and oncology therapeutics (ApDC platform) including AST-201 for liver cancer and AST-203 for solid tumors, serving global pharma partners, Korean hospitals, and South Asia via Appidi Healthcare.
Ownership category
akta.pro rank

Aptamer Sciences industry classification

Industry
Product category
Aptamer-based biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Aptamer therapeutics
  • Cancer diagnostics
  • Drug conjugates
  • Bioanalysis services
  • Targeted drug delivery

Where Aptamer Sciences is headquartered

Location

Headquarters

HQ city
Gyeongju
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Aptamer Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Diagnostic Kit Sales (AptoDetect-Lung): Sales of lung cancer early detection diagnostic kit (AptoDetect-Lung) to hospitals and medical institutions in Korea and international markets through partnership agreements.
  2. Technology Licensing/Out-licensing: License-out deals for ApDC platform pipeline assets (AST-201, AST-202, AST-203, BBB shuttle) to global pharmaceutical companies. Target upfront payments of 480 billion KRW for AST-201 and 200 billion KRW for AST-202.
  3. CRO Services: Revenue from biotech analysis services including GLP/GCLP compliant LC-MS/MS analysis, ADA evaluation, and high-difficulty biomolecular analysis. Acquired ISS (International Scientific Standards) in 2024 for CRO expansion.
  4. Aptamer Material Supply & Royalties: Supply of proprietary aptamer materials to partners for diagnostic kit manufacturing, plus ongoing royalty payments based on sales revenue generated by partners (e.g., Appidi Healthcare partnership for India/South Asia).

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAptoDetect-Lung lung cancer diagnostic test
Unit PricingPay-as-you-goAptoDetect-Lung uses only 5µL of blood per test

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Aptamer Sciences product offering

Product offering

Core offering

Aptamer Sciences develops and commercializes aptamer-based technology platforms spanning two business segments. The diagnostics segment is anchored by AptoDetect-Lung, an in vitro diagnostic kit measuring seven protein biomarkers via Luminex detection for early-stage non-small cell lung cancer detection. The therapeutics segment is built on the ApDC (Aptamer-Drug Conjugate) platform, using modified-nucleic-acid aptamers with proprietary branched linker technology to deliver cytotoxic drugs, radionuclides, and siRNA payloads, with pipeline candidates AST-201 (GPC3-targeted, Phase 1 for liver cancer) and AST-203 (TROP2-targeted, preclinical for pancreatic cancer). The company also operates a GLP/GCLP-compliant CRO bioanalysis business and offers FDA regulatory consulting services.

Product overview

Aptamer Sciences develops and commercializes aptamer-based products across two business segments: (1) Diagnostics — anchored by the AptoDetect™-Lung lung cancer early detection kit, which uses the proprietary AptoMIA platform to measure 7 blood protein biomarkers via Luminex technology and a proprietary algorithm for lung cancer risk scoring; (2) New Drug Development — anchored by the ApDC® (Aptamer-Drug Conjugate) platform, which uses modified-nucleic-acid aptamers with proprietary branched linker technology to deliver cytotoxic drugs, radionuclides, siRNA, and immunomodulators. Key pipeline candidates include AST-201 (GPC3-targeted ApDC for liver cancer, Phase 1), AST-203 (Trop2-targeted MMAE-conjugated ApDC for solid tumors), BBB Shuttle aptamer platform for brain drug delivery, and an insulin receptor allosteric agonist aptamer (AST-101) for diabetes. The company also operates a GLP/GCLP-compliant CRO providing LC-MS/MS bioanalysis and FDA consulting services.

Differentiator

Problem solved

Functional benefit

Brands

  • ApDC: Aptamer-Drug Conjugate platform technology for targeted drug delivery in cancer treatment
  • AptoMIA
  • AptoDetect-Lung
  • BiFAp
  • ApRC
  • BBB Shuttle

Products and services

  • AptoDetect-Lung In vitro diagnostic medical device for early detection of non-small cell lung cancer (NSCLC), measuring 7 protein biomarkers (EGFR1, MMP7, CA6, KIT, CRP, C9, SERPINA3) from 5µL of blood using Luminex-based detection and a proprietary algorithm to generate lung cancer risk scores. Sold to hospitals and medical institutions in Korea and select international markets.
  • CRO Analysis Services GLP/GCLP-compliant bioanalysis services including LC-MS/MS drug analysis, anti-drug antibody (ADA) evaluation, and high-resolution mass spectrometry for metabolite identification. Specialized in high-difficulty biomolecule analysis (peptides, oligonucleotides, ApDC, antibodies) for biotech and pharmaceutical clients requiring IND/NDA support.
  • FDA Analysis Consulting Regulatory consulting service covering FDA-compliant study design, data generation, documentation, and report quality standards for biotech and pharmaceutical clients preparing for US regulatory submissions.

Quantifiable outcome

  • AptoDetect-Lung: Sensitivity 75%, Specificity 92% for NSCLC (Stage I-IV)
  • +4 more outcomes

Companies that use Aptamer Sciences

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles3 records

Aptamer Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Aptamer Sciences partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and supporting.

  • Merck (MSD)coreStrategic or Co-development Partner · 15 April 2026Clinical Trial Collaboration and Supply Agreement (CTCSA) for AST-201 + Keytruda (pembrolizumab) combination therapy evaluation. Aptamer Sciences will conduct Phase 2 trial; MSD supplies Keytruda and provides scientific collaboration. Represents transition from monotherapy to combination immunotherapy development.
  • Curigin (큐리진)coreStrategic or Co-development Partner · 17 June 2025Joint development of aptamer-based bispecific siRNA therapeutic platform. Combines Aptamer Sciences' tissue-specific aptamers with Curigin's dual-targeting siRNA technology for precision gene silencing. Expandable to cancer, inflammatory diseases, fibrosis, and neurodegenerative disorders.
  • Appidi Healthcare (압피디 헬스케어)coreChannel Partner/ Reseller/ Distributor · 20 May 2025Commercialization partnership for AptoDetect-Lung lung cancer diagnostic kit in India and South Asia (Bangladesh, Nepal, Sri Lanka). Appidi handles local manufacturing, clinical trials, regulatory approval, and distribution. Aptamer Sciences supplies aptamer materials and earns royalties on sales.
  • Selki (셀키)supportingTechnology or Integration · 24 April 2025MOU for biotech analysis innovation combining Aptamer Sciences' FDA regulatory expertise and GLP/GCLP analysis services with Selki's AI-based multiomics analysis capabilities and Agentic LLM platform. Aims to elevate ADC and biopharmaceutical analysis quality to FDA standards.
  • Yonsei University College of Medicine (연세대학교 의료원)supportingStrategic or Co-development Partner · 27 June 2024Radiopharmaceutical research collaboration for aptamer-based radionuclide delivery platform. Published in Pharmaceutics journal (top 10%); demonstrated successful 68Ga labeling and PET imaging with EGFRvIII-targeted aptamer in glioblastoma models.
  • International Scientific Standards (ISS)coreStrategic or Co-development Partner · 12 June 2024Acquired ISS (now Aptamer Sciences CRO Center) to expand into GLP/GCLP bioanalysis services for biopharmaceuticals. ISS has 160+ validated analytical methods and completed 110+ clinical analysis projects over 4 years with major Korean pharma companies.
  • NeuraMedi (뉴라메디)supportingStrategic or Co-development Partner · 22 March 2022Joint research on BBB shuttle aptamer-based Parkinson's disease treatment combining Aptamer Sciences' TfR aptamer with NeuraMedi's anti-TLR2 antibody (Tomaralimab) for enhanced brain delivery of therapeutic antibodies.
  • Asymchem (카이라이잉/凯莱英)supportingOEM/ Whitelabel/ Licensing Partner · 4 February 2022CDMO partnership for AST-201 clinical trial material manufacturing and supply. Chinese CDMO for GMP production of aptamer-drug conjugate clinical supplies.
  • Pinobio (피노바이오)supportingStrategic or Co-development Partner · 2 June 2021Joint research on ApDC-based targeted anticancer drug development for glioblastoma and pancreatic cancer. Combines Aptamer Sciences' targeting aptamers with Pinobio's linker-drug conjugation and efficacy evaluation capabilities.

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Aptamer Sciences competitors and assessment

Company assessment

Broad incumbents

  • Daiichi Sankyo: Japanese pharma behind Enhertu (HER2 ADC) and Datroway (TROP2 ADC) - the dominant ADC player. Directly relevant as ApDC competes with ADC technology and the same TROP2 target (AST-203 vs Trodelvy/Datroway).
  • Gilead Sciences: Owns Trodelvy (TROP2 ADC via Immunomedics acquisition), the direct competitor for AST-203. Comparable as a large pharma with both ADC platform and oncology diagnostics (via Foundation Medicine).
  • AstraZeneca: Co-developer of Enhertu and Datroway with Daiichi Sankyo. Also active in radioconjugates and lung cancer diagnostics. Relevant incumbent for ApDC out-licensing competitive landscape.
  • Guardant Health: US liquid biopsy leader (Guardant360, Shield) for oncology diagnostics using blood-based biomarker analysis. Comparable in the multi-biomarker blood test approach used in AptoMIA technology, though at much greater scale.

Direct peers

  • NOXXON Pharma: European clinical-stage biotech developing Spiegelmer aptamer-based therapeutics for cancer. Closest direct peer as a pure-play aptamer therapeutic company, though focused on different targets.
  • Oncimmune Holdings: UK-based company behind EarlyCDT-Lung blood-based lung cancer diagnostic, directly comparable to AptoDetect-Lung. The cost comparison (AptoDetect at ~$150 vs EarlyCDT at ~$450) frames the competitive positioning.
  • Telix Pharmaceuticals: Radiopharmaceutical company developing diagnostic and therapeutic radioligand therapies (Illuccix, PSMA imaging). Directly comparable to Aptamer Sciences' ApRC platform for aptamer-based radioconjugates in cancer.
  • Denali Therapeutics: US biotech specializing in BBB-penetrant therapeutics for neurodegeneration using transferrin receptor (TfR) engineering. Highly comparable to Aptamer Sciences' BBB Shuttle TfR aptamer platform for CNS drug delivery.

Regional players

  • LigaChem Biosciences: Korean ADC developer (KOSDAQ-listed) with similar therapeutic focus on antibody-drug conjugates. Comparable as a domestic Korean peer pursuing next-generation targeted cancer therapies, though using antibodies rather than aptamers.

Emerging players

  • Curigin: Korean siRNA therapeutics company and Aptamer Sciences' joint development partner for aptamer-siRNA conjugates. Partial overlap given the collaboration; represents emerging competition in the targeted RNA therapeutics space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Aptamer Sciences social profiles

Digital presence

Aptamer Sciences compliance and trust

Trust signal

Compliance4 records

Aptamer Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aptamer Sciences leadership team

Management profile

Number of profiles

Profiles8 records

Aptamer Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aptamer Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aptamer Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptamer Sciences

What does Aptamer Sciences do?

Aptamer Sciences develops and commercializes aptamer-based technology platforms spanning two business segments. The diagnostics segment is anchored by AptoDetect-Lung, an in vitro diagnostic kit measuring seven protein biomarkers via Luminex detection for early-stage non-small cell lung cancer detection. The therapeutics segment is built on the ApDC (Aptamer-Drug Conjugate) platform, using modified-nucleic-acid aptamers with proprietary branched linker technology to deliver cytotoxic drugs, radionuclides, and siRNA payloads, with pipeline candidates AST-201 (GPC3-targeted, Phase 1 for liver cancer) and AST-203 (TROP2-targeted, preclinical for pancreatic cancer). The company also operates a GLP/GCLP-compliant CRO bioanalysis business and offers FDA regulatory consulting services.

Is Aptamer Sciences a public or private company?

Aptamer Sciences is a public company. It is classified as public and is currently operating.

When was Aptamer Sciences founded?

Aptamer Sciences was founded in 2011. It employs 11 to 50 people.

Where is Aptamer Sciences based?

Aptamer Sciences is headquartered in Gyeongju, South Korea, in the Asia region.

How does Aptamer Sciences make money?

Four revenue lines are on record. Diagnostic Kit Sales (AptoDetect-Lung) is the primary driver. The others are technology Licensing/Out-licensing, CRO Services and aptamer Material Supply & Royalties.

Who are Aptamer Sciences's main competitors?

Broad incumbents on record are Daiichi Sankyo, Gilead Sciences, AstraZeneca and Guardant Health. Direct peers are NOXXON Pharma, Oncimmune Holdings, Telix Pharmaceuticals and Denali Therapeutics. LigaChem Biosciences is listed as a regional player. Curigin is listed as an emerging player.

Does Aptamer Sciences have an API?

No public API is recorded for Aptamer Sciences.

What industry is Aptamer Sciences in?

Aptamer Sciences's product category is Aptamer-based biotechnology. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Aptamers (Nucleic Acid & Peptide) Market 2014-2017 - Forecasts to 2025: Key Players are Aptamer, Aptamer Sciences, Aptagen, Base Pair Biotechnologies & OphthotechResearch and Markets has published a market analysis report projecting the global aptamers market to reach USD 8.91 billion by 2025, driven by advancements in aptamer development technologies, increasing R&D investment, and advantages over traditional antibodies such as chemical synthesis that eliminates batch-to-batch variation. Integrated DNA Technologies introduced Ultramers, a next-generation product containing aptamer template lengths up to 200 bases suitable for gene and clone construction applications. Aptamer Sciences unveiled a multiprotein biomarker assay in March 2017 for early detection of non-small cell lung cancer, representing one of the notable product launches in the sector.PR NewswireAptamers Market Analysis By Types (Nucleic Acid & Peptide), By Application (Diagnostics, Therapeutics, Research & Developments, Others), By Region, And Segment Forecasts, 2014 - 2025Grand View Research published a report projecting the global aptamers market to grow to USD 8.91 billion by 2025, driven by technological advancements, increasing R&D investments, and advantages of aptamers over traditional antibodies. The report highlights specific product launches including Integrated DNA Technologies' Ultramers and Aptamer Sciences' multiprotein biomarker assay for lung cancer detection as key growth drivers. However, it identifies clinical trial failures and low awareness in developing regions as factors that may hinder market expansion.